Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1940020 | 0.91 | PTGDR2 (0.80) | PTGDR2 | |
| Qav680 SCHEMBL29376454 | 0.89 | PTGDR2 (1.00) | PTGDR2 | |
| Qav680 SCHEMBL1941180 | 0.89 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1940811 | 0.87 | PTGDR2 (0.78) | PTGDR2 | |
| SCHEMBL1939847 | 0.87 | PTGDR2 (0.81) | PTGDR2 | |
| SCHEMBL2922874 | 0.86 | PTGDR2 (0.59) | PTGDR2 | |
| SCHEMBL1939701 | 0.85 | PTGDR2 (0.80) | PTGDR2 | |
| SCHEMBL1941425 | 0.85 | PTGDR2 (0.61) | PTGDR2 | |
| SCHEMBL2922859 | 0.84 | PTGDR2 (0.57) | PTGDR2 | |
| SCHEMBL1940826 | 0.84 | PTGDR2 (0.79) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169251-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2015-10-27 | — | — | US | disclosed |
| US-20140309254-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG | 2014-10-16 | — | — | US | disclosed |
| US-8791256-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-20130267518-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| US-8470848-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-06-25 | — | — | US | disclosed |
| US-8455645-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| EP-1761529-B3 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-20100210610-A1 | Organic compounds | BALA KAMLESH JAGDIS | 2010-08-19 | — | — | US | disclosed |
| US-20100204225-A1 | Organic compounds | BALA KAMLESH JAGDIS | 2010-08-12 | — | — | US | disclosed |
| US-7666878-B2 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| US-20080312230-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1963317-A1 | USE OF PYRROLO [2 , 3-B]PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| EP-1761529-B1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007068418-A1 | USE OF PYRROLO [2 , 3-B] PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| EP-1761529-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123731-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267518-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | HRH2, QDPR, AVPR2 | PTGDR2 29/4885 |
| US-20140309254-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | HRH2, QDPR, AVPR2 | PTGDR2 29/4885 |
| US-20100210610-A1 | Organic compounds | SLC10A6, SLCO1B3, OPRM1 | PTGDR2 1399/4885 |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | CCR1, CCL2, CCL11 | PTGDR2 92/4885 |
| US-20100204225-A1 | Organic compounds | SLC10A6, SLCO1B3, OPRM1 | PTGDR2 1399/4885 |
| US-20080312230-A1 | Organic Compounds | OPRM1, OPRL1, OPRD1 | PTGDR2 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.